Journal
METABOLITES
Volume 12, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/metabo12070586
Keywords
selective antagonist of adenosine receptors; DPCPX; istradefylline; sodium selenite; forced swim test; tail suspension test; BDNF; gene expression; mice
Categories
Funding
- Statutory Activity of the Medical University of Lublin, Poland [DS48]
Ask authors/readers for more resources
The study determined that the co-administration of sodium selenite with selective adenosine A1 and A2A antagonists has antidepressant-like potential in mice, enhancing efficacy and altering gene expression levels. This combination may provide a new therapeutic strategy for patients with depression.
The main goal of this study was to determine the antidepressant-like potential of the co-administration of sodium selenite (Se) and the selective adenosine A1 and A2A antagonists DPCPX and istradefylline (IST), respectively, in mice despair tests. Biochemical studies were performed to elucidate the action mechanisms of the investigated treatment strategies. The results confirmed that, when administered by itself, Se exerts an antidepressant-like effect in the FST and TST and that this activity is dose-dependent. Further experiments demonstrated that Se (0.25 mg/kg) significantly enhanced the activity of mice in both tests when co-administered with DPCPX (1 mg/kg) and IST (0.5 mg/kg) at doses which would be ineffective if administered individually. Our research revealed that neither DPCPX, IST, nor Se or combinations of the tested substances induced significant changes in the brain-derived neurotrophic factor (BDNF) levels in mice serum vs. the NaCl-treated group. However, we observed a decrease in the mRNA level of antioxidant defense enzymes. Molecular studies also showed changes in the expression of the Slc6a15, Comt, and Adora1 genes, particularly after exposure to the combination of Se and DPCPX, which indicates a beneficial effect and may help to explain the key mechanism of the antidepressant effect. The combination of Se with substances attenuating adenosine neurotransmission may become a new therapeutic strategy for patients with depression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available